Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review.

Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review. Expert Rev Anticancer Ther. 2018 Jul 11;: Authors: Babey H, Quéré G, Descourt R, Le Calloch R, Lanfranco L, Nousbaum JB, Cornec D, Tison A, Chouaid C Abstract INTRODUCTION: Because of their efficacy against numerous cancers, immune-checkpoint inhibitors (ICIs), anti-cytotoxic T-lymphocyte antigen-4 (CTLA4) and anti-programmed cell-death (PD-1) monoclonal antibodies, are being used ever more often in oncology. However, some patients were excluded from clinical trials because of their comorbidities, despite their potentially higher cancer frequencies, as is the case for immunocompromised patients. Areas covered: We analyzed reported preclinical and clinical information and evaluated the risk/benefit ratio for 4 immunocompromised populations: people living with human immunodeficiency virus (PLHs), solid-organ-transplant recipients, recipients of hematopoietic stem-cell allografts and patients with autoimmune diseases. Expert commentary: Information available in the literature is fragmentary and scarce, making it difficult to evaluate the risk/benefit ratio. It can, nonetheless, be noted that ICI use in PLHs seems possible. For solid-organ-transplant recipients, the risk for the graft seems elevated. For the other 2 populations, it is difficult to conclude at this time. PMID: 29995451 [PubMed - as supplied by publisher]
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research